-
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients
Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT…
-
Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer
As early as 2017, when immunotherapy was just introduced for the treatment of liver cancer, Korean scholars began clinical trials of combining radiotherapy with immunotherapy. In a clinical study published…
-
Dr. Guohong Han: Combining Targeted Therapy to Reduce Postoperative Liver Cancer Recurrence and Prolong Survival in Cirrhotic Patients with Anticoagulation
Hepatology Digest: Liver cancer immunotherapy has been a major focus of this year’s conference, particularly the research presented on June 23rd regarding adjuvant targeted immunotherapy for high-risk liver cancer recurrence…
-
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections
Chronic hepatitis B (CHB) remains a global medical burden. According to the guidelines released by the European Association for the Study of the Liver (EASL) in 2017, the natural history…
-
Strategy First! UCLI-ICML Joint Session Lays Foundation for Collaboration
Editor’s note: 01. Confidence, Cooperation, Progress — UCLI-ICML Joint Session Lays Foundation for Collaboration Dr. Ma: The UCLI-ICML joint session has been held four times to date. Ten years ago,…
-
APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China
Acute-on-Chronic Liver Failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function on the background of chronic liver disease, accompanied by liver and/or extrahepatic organ failure. It poses a significant challenge in internal medicine due to its high short-term mortality rate of 50% to 90%. Early prediction of the risk of ACLF…
-
ID Week Commentary | Dr. Junyan Qu: Real-world Efficacy Comparison of CT vs. CZA in Treating MDR-PA Infections
Dr. Junyan Qu Infectious Diseases Center, West China Hospital of Sichuan University Research Introduction A multicenter, observational study to compare the effectiveness of eftazidim vibactam versus eftolozane azobactam for multidrug-resistant…
-
Second-Line Treatment for Advanced HCC – Interpretation of the “CSCO Primary HCC Diagnosis and Treatment Guidelines (2022 Edition)
Targeted Therapies 1. Regorafenib The RESORCE study solidified the position of regorafenib as a second-line treatment for advanced HCC. Compared to placebo, regorafenib significantly extended the median overall survival (mOS)…
Connecting Medical Expertise through Media